4.6 Article

Molecular Characterization of the Response to Conventional Chemotherapeutics in Pro-B-ALL Cell Lines in Terms of Tumor Relapse

期刊

GENES
卷 13, 期 7, 页码 -

出版社

MDPI
DOI: 10.3390/genes13071240

关键词

drug response; tumor relapse; acute lymphoblastic leukemia; cytostatics; cytarabine; dexamethasone

资金

  1. BMBF [03V0396]
  2. European Union (EFRE, European Fund for Regional Development) [GHS-15-0019]
  3. Professorinnenprogramm Universitat Rostock

向作者/读者索取更多资源

The optimal application of chemotherapeutic agents in a specific temporal sequence to rapidly reduce tumor load and improve therapeutic efficacy is still poorly understood. Clinical optimization of drug efficacy is restricted by an incomplete understanding of molecular mechanisms and tumor relapse. Transcriptomic drug signatures and network-based approaches can help identify key driver genes and miRNAs that control relapse mechanisms. Studying genes and miRNAs involved in Dexa-resistance and chemosensitivity may provide insights into tumor relapse processes.
Little is known about optimally applying chemotherapeutic agents in a specific temporal sequence to rapidly reduce the tumor load and to improve therapeutic efficacy. The clinical optimization of drug efficacy while reducing side effects is still restricted due to an incomplete understanding of the mode of action and related tumor relapse mechanisms on the molecular level. The molecular characterization of transcriptomic drug signatures can help to identify the affected pathways, downstream regulated genes and regulatory interactions related to tumor relapse in response to drug application. We tried to outline the dynamic regulatory reprogramming leading to tumor relapse in relapsed MLL-rearranged pro-B-cell acute lymphoblastic leukemia (B-ALL) cells in response to two first-line treatments: dexamethasone (Dexa) and cytarabine (AraC). We performed an integrative molecular analysis of whole transcriptome profiles of each treatment, specifically considering public knowledge of miRNA regulation via a network-based approach to unravel key driver genes and miRNAs that may control the relapse mechanisms accompanying each treatment. Our results gave hints to the crucial regulatory roles of genes leading to Dexa-resistance and related miRNAs linked to chemosensitivity. These genes and miRNAs should be further investigated in preclinical models to obtain more hints about relapse processes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据